Testosterone Lawsuits Consolidated in Illinois Federal Court, Bernstein Liebhard LLP Reports

The Firm is investigating testosterone treatment lawsuits on behalf of men who allegedly suffered heart attacks, strokes, blood clots and other cardiovascular problems due to their use of low testosterone therapy.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInShare on PinterestEmail a friend
Free Case Review
Our Firm has heard from numerous men who allegedly suffered serious heart events due to their use of AndroGel and other low testosterone therapies.

New York, New York (PRWEB) June 07, 2014

A federal judicial panel has established a multidistrict litigation for all federally-filed testosterone lawsuits (http://www.testosteronelawsuitclaims.com/) involving drugs like AndroGel in the U.S. District Court, Northern District of Illinois. According to the Transfer Order issued by the U.S. Judicial Panel on Multidistrict Litigation on June 6, 2014, the low testosterone therapy litigation will be presided over by U.S. District Judge Matthew F. Kennelly, who the Panel characterized an “experienced MDL jurist.”

“Our Firm has heard from numerous men who allegedly suffered serious heart events due to their use of AndroGel and other low testosterone therapies. This litigation is likely to be large, and consolidating the cases will allow the claims to proceed more efficiently,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free and confidential case reviews to individuals who allegedly have suffered heart attacks, strokes, dangerous blood clots and other serious heart events due to their use of testosterone treatment therapies. (In re: Testosterone Replacement Therapy Product Liability Litigation - MDL No. 2545)

Testosterone Lawsuit Allegations
The JPML’s Transfer Order initially consolidates 45 actions that allege the use of testosterone therapies caused men to suffer life-threatening cardiovascular events. The Order further notes that 81 potentially related testosterone lawsuits are also pending in other federal districts around the U.S, and that plaintiffs predict that the number of filings could ultimately grow into the thousands. The Panel opted to create an industry-wide multidistrict litigation because a number of the actions involve more than one testosterone drug. The Northern District of Illinois was chosen for the litigation because the majority of claims had already been filed in that district. In assigning the docket to Judge Kennelly, the JPML noted that he was already presiding over those claims and has taken initial steps to organize the litigation.

Prescription testosterone therapies are approved to treat low testosterone in men who suffer from the condition due to an underlying medical issue. Medications in this class include:*

  •     Axiron
  •     AndroDerm
  •     AndroGel
  •     Bio-T Gel
  •     Delatestryl
  •     Depo-Testosterone
  •     Foresta
  •     Striant
  •     Testopel
  •     Testim

According to court records, testosterone lawsuits have been mounting in U.S. courts since January 2014, when the U.S. Food & Drug Administration (FDA) announced that it was reviewing the heart risks associated with these medications. The FDA decided to launch its review after two studies found a high rate of heart attacks, strokes and death in older men and those with preexisting heart problems who received testosterone therapy.

Men who allegedly experienced life-threatening heart events due to low testosterone therapy may be entitled to compensation for their injury-related damages, including medical bills, lost wages, pain and suffering, and more. Learn more about filing a testosterone treatment lawsuit by calling our Firm today at 800-511-5092.

*accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.SearchAction&SearchType=BasicSearch&searchTerm=testosterone&Search_Button=Submit, FDA

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3 billion on behalf of our clients. The Firm has been named by The National Law Journal to the Plaintiffs’ Hot List, recognizing the top plaintiffs firms in the country, for the past 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list every year since it was first published in 2003.

Bernstein Liebhard LLP represents the victims of defective drugs and medical devices on a contingency-fee basis, and our clients are never expected to pay attorneys fees unless their case results in a successful recovery on their behalf. New York State’s contingency fee cap rules generally limit those fees to 33 1/3% of the total recovery. As a result, the Firm’s fees can be significantly lower than those assessed by attorneys in other states, which depending on the law may amount to as much as 40% or more of a plaintiff’s recovery.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:

Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com
http://www.testosteronelawsuitclaims.com/
https://plus.google.com/115936073311125306742?rel=author